AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02402101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: active tDCS
Description: Intensity 2 mA during 20 minutes
Study NCT02402101 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Procedure: sham tDCS
Description: sham condition as delivered by the stimulator
Study NCT01257503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: liquid made to look like the active homeopathic remedy
Study NCT04238208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 5% patch
Description: 5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm
Study NCT04238208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine 5% patch
Description: 5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm
Study NCT04238208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% Patch, Per 10 Square Centimeters
Description: 8% Capsaicin patch \[8% w/w\] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)
Study NCT00890942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone
Description: naloxone 0.4mg.(1 ml) intramuscular
Study NCT00890942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 1 ml IM
Study NCT03888521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resound Relief smartphone app
Description: The intervention is a smartphone app which has been developed to include a wide range of sounds and techniques aimed at reducing the impact of tinnitus.
Study NCT03105973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-Enabled CBT Treatment
Description: CBT-based modules delivered via tablet over 4 weeks.
Study NCT01362673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: Oral single 5 mg dose as one 5 mg tablet
Study NCT01362673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: Oral single 10 mg dose as one 10 mg tablet
Study NCT01362673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: Oral single 30 mg dose as three 10 mg tablets
Study NCT01362673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral single dose as matching placebo
Study NCT01362673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: Oral multiple 20 mg doses as two 10 mg tablets for 12 days
Study NCT01362673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral multiple doses as matching placebo for 12 days
Study NCT02123732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DbXell
Study NCT02123732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01009515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, temozolomide
Description: Combination chemotherapy was administered for up to 6 cycles
Study NCT02690051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeSmooth peripheral stent
Description: patients treated with the BeSmooth Peripheral Stent System
Study NCT02180165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: 300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
Study NCT02180165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: 300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
Study NCT03038763 — intervention group
Intervention type: OTHER
Intervention: Eligibility Screening
Description: Investigators will call eligible mothers to screen for the possibility that eligible mothers may have passed HCV on to adult children. Investigators will consent these mothers to contact the adult child(ren), as the child(ren) must be informed of the mother's HCV status, if not already known.
Study NCT03038763 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HCV test
Description: Adult children will be invited to Penn or a Penn affiliate to have labwork, testing HCV antibody and HCV quant. If the quant comes back positive, investigators will also test genotype and fibrosure.
Study NCT04449458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Me
Description: 12 session smoking cessation intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
Study NCT01393470 — intervention group
Intervention type: PROCEDURE
Intervention: Screening for cervical cancer
Description: Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
Study NCT01377571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: 2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
Study NCT00876876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
Study NCT00876876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lixivaptan
Description: Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
Study NCT00320931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid PET/CT
Description: Rest and vasodilation stress rubidium PET and coronary angiography with CT were performed using standard doses for clinically indicated studies.
Study NCT01146275 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiologial breast examination
Description: MRI of breast, mammography and ultrasound of breast
Study NCT01542073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BNOTA-PRGD2
Description: Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
Study NCT02937428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Look away from the needle
Description: Participant looks away from the needle during vaccination
Study NCT02937428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Look at the needle
Description: Participant looks at the needle during vaccination
Study NCT01924988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Embolization with Embosphere Micropsheres
Description: Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudendal or obturator branches as well.~The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries.
Study NCT01865188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: Experimental monotherapy doses
Study NCT01865188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Active comparator monotherapy doses
Study NCT01865188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 and amlodipine combination
Description: Experimental combination doses
Study NCT01865188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator dose
Study NCT02556658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General anesthesia managed by the Smartpilot® View
Description: General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
Study NCT02556658 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia managed without the Smartpilot® View
Description: General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
Study NCT02777710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
Study NCT04503616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Description: Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
Study NCT02777710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
Study NCT00152360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: See Detailed Description.
Study NCT02239354 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-01™ Combination Product
Description: Biologic and Device
Study NCT03603054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active neck mobilization
Description: The subjects, receive an active neck mobilization intervention.
Study NCT03603054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Mobilization of the sciatic nerve
Description: The subjects, receive an active sciatic nerve mobilization intervention.
Study NCT01892267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG-J placement
Description: PEG-J placement
Study NCT01892267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEG-J placement
Description: PEG-J placement
Study NCT03702517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lateral stair walking exercise
Description: 15 minutes of lateral stair walking exercise
Study NCT03702517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lateral stair walking exercise
Description: 15 minutes of lateral stair walking exercise
Study NCT03702517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional physiotherapy
Description: strengthening exercise, balance training and gait training
Study NCT04449458 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Positively Living
Description: 12 session healthy living intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
Study NCT03702517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy
Description: strengthening exercise, balance training and gait training
Study NCT00760500 — intervention group
Intervention type: OTHER
Intervention: Nasopharyngeal Swab
Description: Nasopharyngeal Swab
Study NCT05631600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manuka honey
Description: The honey was applied with special designed cannula. The dosage is not exactly define so we inject the amount of honey until until the excess of the material was observed in the sulcus.
Study NCT02853851 — intervention group
Intervention type: OTHER
Intervention: interviews
Description: Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).
Study NCT03731039 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Pain assessment, Anxiety assessment, Depression assessment
Study NCT04500730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shaoyao Gancao Decoction Jiawei
Description: Study herb will be prescribed for 28 consecutive days. Study follow up will be offered every 7 days till 56th day after enrolment.~Daily leg cramps log will be filled in by each individual everyday from day 0 to day 56.
Study NCT01914757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
Study NCT01914757 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 52 inclusive.
Study NCT03502096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: To-Go container
Description: Subjects were provided a to-go container in which leftover foods would be packaged
Study NCT03502096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects were not provided a to-go container with the meal
Study NCT03537612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
Study NCT03537612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
Study NCT05258643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood analysis
Description: Venipuncture and collection of serum and whole blood
Study NCT03875768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tracking plus coaching
Description: Participants will track their nutrition intake every day for six months using a study app and receive tailored feedback via text message based on their nutritional intake and adherence to the DASH dietary pattern. If necessary, they will receive responsive coaching from a Nourish registered dietitian in order to increase adherence to the DASH dietary pattern and their engagement with the intervention.
Study NCT05130918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phenolmicin P3 and Bosexil suppository
Description: The suppository we herein investigated includes different active principles, namely: Bosexil®, that is a vegetal extract derived from the resin of the Boswellia serrata, a plant native to India. It has already been published that the Boswellic acids contained show anti-inflammatory and antioxidant properties in a variety of inflammatory diseases whose physio-pathological pathways are shared with those of prostatitis; phenolmicin P3 is a polyphenolic extract derived from beehive propolis, that also demonstrated anti-inflammatory and antioxidant properties in preclinical reports. It has also been reported to have the ability to create a microenvironment hostile to the reproduction of pathogenic bacteria.
Study NCT00922233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel
Description: oral contraceptive pills
Study NCT00315146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Study NCT02781584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Administered orally once daily
Study NCT02781584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: Administered orally once daily
Study NCT04100993 — intervention group
Intervention type: OTHER
Intervention: No intervention used
Description: No intervention used
Study NCT02959463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02959463 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo palliative radiation therapy
Study NCT02959463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00272272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Listening to Music while standing
Study NCT02797379 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychoeducation
Description: The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
Study NCT03904550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium + Neostigmine
Description: Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate
Study NCT03904550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium + Sugammadex
Description: Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
Study NCT01056926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit smoking
Description: Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
Study NCT01056926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
Study NCT01056926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
Study NCT02502968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02502968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study NCT02502968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Study NCT02502968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for BL-8040)
Description: Powder for solution for injection manufactured to mimic BL-8040
Study NCT02150356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aleurone
Description: Diet based in aleurone-enriched products for a period of 8 weeks.
Study NCT02150356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Diet based on refined cereal products for a period of 8 weeks.
Study NCT00315146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise training to maximize muscle power
Study NCT00315146 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hypocaloric diet
Study NCT00315146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Study NCT00315146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00315146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04362332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine Sulfate
Description: cluster randomized
Study NCT02959463 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo hemithoracic radiation therapy
Study NCT00630643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NI-0401 (anti-CD3 mAB)
Description: 0.05 mg up to 10 mg